Literature DB >> 16719905

Association study of genetic variants of pro-inflammatory chemokine and cytokine genes in systemic lupus erythematosus.

Elena Sánchez1, José M Sabio, José L Callejas, Enrique de Ramón, Rosa Garcia-Portales, Francisco J García-Hernández, Juan Jiménez-Alonso, Ma Francisca González-Escribano, Javier Martín, Bobby P Koeleman.   

Abstract

BACKGROUND: Several lines of evidence suggest that chemokines and cytokines play an important role in the inflammatory development and progression of systemic lupus erythematosus. The aim of this study was to evaluate the relevance of functional genetic variations of RANTES, IL-8, IL-1alpha, and MCP-1 for systemic lupus erythematosus.
METHODS: The study was conducted on 500 SLE patients and 481 ethnically matched healthy controls. Genotyping of polymorphisms in the RANTES, IL-8, IL-1alpha, and MCP-1 genes were performed using a real-time polymerase chain reaction (PCR) system with pre-developed TaqMan allelic discrimination assay.
RESULTS: No significant differences between SLE patients and healthy controls were observed when comparing genotype, allele or haplotype frequencies of the RANTES, IL-8, IL-1alpha, and MCP-1 polymorphisms. In addition, no evidence for association with clinical sub-features of SLE was found.
CONCLUSION: These results suggest that the tested functional variation of RANTES, IL-8, IL-1alpha, and MCP-1 genes do not confer a relevant role in the susceptibility or severity of SLE in the Spanish population.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16719905      PMCID: PMC1488833          DOI: 10.1186/1471-2350-7-48

Source DB:  PubMed          Journal:  BMC Med Genet        ISSN: 1471-2350            Impact factor:   2.103


Background

Systemic lupus erythematosus (SLE) is a chronic and systemic autoimmune disease with a complex pathogenesis involving multiple genetic and environmental factors. The disease is characterized by autoantibody production, abnormalities of immune-inflammatory system function and inflammatory manifestation in several organs. Although the pathogenesis of SLE is unknown, the increased concordance of SLE in monozygotic versus dizygotic twins and familial clustering provide evidences for the role of genetic factors in this disorder [1]. However, the genetic background of SLE is thought to be complex and involves multiple genes encoding different molecules with significant functions in the regulation of the immune system [1-4]. Among the genetic factors believed to influence susceptibility to SLE, the major histocompatibility complex (MHC) alleles show the most significant association. Importantly, several recent studies show that non-HLA genes play a role in the development of SLE [1-4]. In this respect, there are several lines of evidence that chemokines and cytokines play an important role in the inflammatory development and progression of autoimmune diseases as SLE [5-7]. Furthermore, it has been show that SLE patients show an up-regulation of inflammatory molecules [8,9]. Regulated upon activation, normal T cell expressed and secreted (RANTES), interleukin 8 (IL-8) and monocyte chemoattractant protein-1 (MCP-1) are involved in the physiology and pathophysiology of acute and chronic inflammatory processes, by recruitment of monocytes, T lymphocytes and eosinophils to sites of inflammation [10,11]. Substantial evidence suggest that IL-8 and MCP-1, contribute to kidney injury in the glomerulonephritis of SLE, through glomerular leukocyte infiltration [12,13]. Serum levels of these inflammatory chemokines (RANTES, IL8 and MCP-1) are significantly higher in SLE patients than in control subjects, and correlated significant with SLEDAI score, suggesting a role in the pathogenesis of the disease [9]. As a consequence of renal disease, increased urine MCP-1 and urine IL-8 (uMCP-1, uIL-8) levels can be detected in SLE patients during active renal disease [14]. Interestingly some genetic variants within regulatory regions of these genes can affect the transcriptional activity and subsequent protein expression in human. For, RANTES the SNPs -403 G/A (rs2107538) and R3 (rs2306630) T/C, for IL-8 -353 T/A (rs4073) and for +781 C/T (rs2227306) and MCP-1 -2518 G/A (rs1024611) have been correlated to mRNA and or protein expression [15-17]. In addition to these three genes, IL-1α also constitutes a strong candidate gene for SLE, since it is a proinflammatory cytokine that plays and important role in initiating and modulating the immune responses. There is a functional polymorphism in the promoter region of IL-1α gene at position -889 C/T (rs1800587), and the -889 C homozygous genotype has been associated with significantly lower transcriptional activity of the IL-1α gene and lower levels of IL-1α in plasma compared with the TT genotype [18]. Overall, the chemokines RANTES, IL-8, MCP-1and cytokine IL-1α are strong candidate genes for which genetic association studies can shed light on the underlying mechanisms causing the immune dysregulation, such as inappropriate T cell activation or trafficking in SLE. Therefore, the aim of this work was to test for association of the reported functional polymorphisms in RANTES, IL-8, MCP-1 and IL-1α with SLE susceptibility.

Methods

Patients

Peripheral blood samples were obtained after written informed consent from 500 SLE patients meeting the American College of Rheumatology (ACR) criteria for SLE [19]. These patients were recruited from five Spanish hospitals: Hospital Virgen de las Nieves and Hospital Clinico (Granada), Hospital Virgen del Rocio (Seville) and Hospital Carlos-Haya and Hospital Virgen de la Victoria (Malaga). Similarly, blood was taken from 481 blood bank and bone marrow donors of the corresponding cities that were included as healthy individuals. Both patient and control groups were of Spanish Caucasian origin and were matched for age and sex. Eighty seven percent of the SLE patients were women, the mean age of SLE patients at diagnosis was 43 ± 13.3 years and the mean age at disease onset of SLE symptoms was 32 ± 15 years. The SLE clinical manifestations studied were articular involvement (76%), renal affectation (37%), cutaneous lesions (62%), hematopoietic alterations (73%), photosensivity (51%), neurological disease (17%) and serositis (28%). The study was approved by all local ethical committees from the corresponding hospitals.

Genotyping

For all the considered SNPs, samples were genotyped using a pre-developed TaqMan allelic discrimination assay. Table 1 shows the part number and reference of each SNP (Applied Biosystems, Foster City, CA, USA). PCR was carried out with mixes consisting of 8 ng of genomic DNA, 2.5 μl of Taqman master mix, 0.125 μl of 20x assay mix and ddH2O up to 5 μl of final volume. The following amplification protocol was used: denaturation at 95°C for 10 min, followed by 40 cycles of denaturation at 92°C for 15 sec and annealing and extension at 60°C for 1 min. After PCR, the genotype of each sample was attributed automatically by measuring the allelic specific fluorescence on the ABI PRISM 7900 Sequence Detection Systems using the SDS 2.2.2 software for allelic discrimination (Applied Biosystems, Foster City, CA, USA).
Table 1

Taqman probes part number used for genotyping.

PolymorphismsPart number
RANTES -403 G/A (rs2107538)C_15874407_10
RANTES R3 C/T (rs2306630)C_26625663_10
IL-8 -353 A/T (rs4073)C_11748116_10
IL-8 +781 C/T (rs2227306)C_11748169_10
IL-1α -889 C/T (rs1800587)C_9546481_20
MCP-1 -2518 G/A (rs1024611)C_2590362_10
Taqman probes part number used for genotyping.

Statistic analysis

Allele and genotype frequencies were obtained by direct counting. Hardy-Weinberg equilibrium and statistical analysis to compare allelic and genotypic distributions were performed using the chi-square test. Odds ratio (OR) with 95% confidence intervals (95%CI) were calculated according to Woolf's method. The software used was StatCalc program (Epi Info 2002; Centers of Disease Control and Prevention, Atlanta, GA, USA). For the haplotype analysis, pair-wise linkage disequilibrium measures were investigated and haplotypes were constructed using the expectation-maximization (EM) algorithm implemented in UNPHASED software [20]. P values below 0.05 were considered statistically significant. The power of the study to detect an effect of a polymorphism in disease susceptibility was estimated using the Quanto v 0.5 software (Department of Preventive Medicine University of Southern California, CA, USA).

Results

Table 2 shows the allele and genotype distribution of the RANTES,IL-8, IL-1α, and MCP-1 polymorphisms. For all polymorphisms, the distribution of genotypes did not deviate from that expected from populations in Hardy-Weinberg equilibrium.
Table 2

Allele and genotype frequencies of RANTES, IL-8, MCP-1 and IL-1α polymorphisms in SLE patients and healthy controls.

SLE patientsControlsPOR (95%CI)
RANTES -403n%n%

Genotypes
GG36973.833369.30.1
GA11322.6135280.040.75 (0.55–1.01)
AA183.6132.70.4
Alleles
G8518580183.3
A1491516116.70.2

RANTES R3n%n%

Genotypes
CC32673.834077.60.06
CT10423.59020.60.3
TT122.781.80.4
Alleles
C75685.577088
T12814.5106120.1

IL-8 -353n%n%

Genoypes
AA12628.712530.30.6
AT2154919447.10.5
TT9822.39322.60.9
Alleles
A46753.244453.8
T41146.838046.20.7

IL-8 +781n%n%

Genotypes
CC1643514333.30.6
CT2385122151.50.8
TT65146515.20.6
Alleles
C56660.650759.1
T36839.435140.90.5

IL-1α -889n%n%

Genotypes
CC22052.720949.70.4
CT16439.316639.50.9
TT337.94510.70.2
Alleles
C60472.458469.5
T23027.625630.50.2

MCP-1 -2518n%n%

Genotypes
AA23857.225058.50.6
AG17335154360.7
GG397.8235.40.1
Alleles
A73974.665476.6
G25125.420023.40.3
Allele and genotype frequencies of RANTES, IL-8, MCP-1 and IL-1α polymorphisms in SLE patients and healthy controls.

RANTES typing

Genotyping of RANTES -403 G/A and R3 T/C was performed in 500 and 442 SLE patients and 481 and 438 healthy controls, respectively (table 2). No statistically significant differences were observed when the allele and genotype distribution was compared between SLE patients and healthy controls. Also, we found no association for the two marker haplotypes (table 3).
Table 3

Haplotype frequencies for RANTES and IL-8 polymorphisms in SLE patients and controls.

GeneHaplotypeSLE patientsHealthy controlsPvalueOR (95%CI)
RANTES

-403A/R3C25 (5.7)25 (5.8)ns
-403A/R3T50 (11.3)40 (9.3)ns
-403G/R3C355 (80.7)356 (83.4)ns
-403G/R3T10 (2.3)6 (1.5)ns

IL-8

-353T/+781C69 (8.6)48 (6.2)0.081.41 (0.94–2.10)
-353T/+781T316 (39.2)303 (39.4)ns
-353A/+781C403 (50)406 (52.7)ns
-353A/+781T18 (2.2)13 (1.7)ns
Haplotype frequencies for RANTES and IL-8 polymorphisms in SLE patients and controls.

IL-8 typing

IL-8 -353 T/A and +781 C/T was genotyping in 439 and 467 SLE patients and 412 and 429 healthy controls, respectively for each polymorphism. We found a similar distribution in the allele and genotype frequencies between SLE patients and controls for both genetic variants. The haplotype estimation for the -353 T/A and +781 C/T IL-8 polymorphisms revealed a strong degree of linkage disequilibrium between the two variants (D' = 0.9) and showed a slight but non-significant increase of the -353T-+781C haplotype in SLE patients (8.5% vs 6.2%, P = 0.08, OR = 1.41, 95%CI = 0.94–2.10) (Table 3).

IL-1α typing

IL-1α -889 was typing in 417 SLE patients and 420 healthy controls. We did not find any significant difference when allele and genotype frequencies were compared between SLE patients and healthy controls.

MCP-1 typing

Table 2 show the allele and genotype distribution of the MCP-1 -2518 A/G polymorphism in 450 SLE patients and 427 controls. No significant differences in the allele and genotype frequencies of the MCP-1 -2518 A/G polymorphism were found between SLE patients and controls. In addition, available clinical features of patients with SLE were analysed for possible association with the different alleles or genotypes of these polymorphisms. When we stratified SLE patients according to the presence of renal involvement, no statistically significant differences were observed in the distribution of RANTES -403, RANTES R3, IL-1α -889 and MCP-1 -2518 polymorphisms between SLE patients with and without lupus nephritis (table 4). Regarding IL-8 polymorphisms, the AT -353 genotype and the -353T/+781C haplotype showed an increased among lupus patients without nephritis compared with patients with nephritis (39.2% vs 49.4%, P = 0.03, OR = 0.66, 95%CI = 0.44–0.99 for AT -353 genotype) (5.7% vs 10%, P = 0.05, OR = 0.55, 95%CI = 0.28–1.05 for -353T/+781C haplotype) (table 4).
Table 4

Relationship between RANTES, IL-8, MCP-1 and IL-1α polymorphisms and the presence of nephritis in SLE Spanish patients.

SLE with nephritisSLE without nephritisPOR (95%CI)
RANTES -403n%n%

Genotypes
GG13673.5230730.9
GA4423.87122.50.7
AA52.7144.40.3
Alleles
G5414.69915.7
A31685.453184.30.6

RANTES R3n%n%

Genotypes
CC8977.422568.80.08
CT23209228.10.1
TT32.61030.8
Alleles
C20187.454282.9
T2912.611212.10.1

IL-8 -353n%n%

Genoypes
AA4726.75922.40.3
AT6939.213049.40.030.66 (0.44–0.99)
TT6034.17428.20.2
Alleles
A16346.324847.2
T18953.727852.80.8

IL-8 +781n%n%

Genotypes
CC7439.69935.30.3
CT8545.4151540.07
TT28153010.70.2
Alleles
C23362.334962.3
T14137.721137.70.9

IL8 -353T/+781C

Haplotypes
-353T/+781C155.739100.050.55 (0.21–8.05)
-353T/+781T10439.714938.20.7
-353A/+781C14053.419349.50.3
-353A/+781T31.292.30.3

IL-1α -889

Genotypes
CC7249.313850.90.7
CT5940.411542.40.7
TT1510.3186.70.2
Alleles
C20369.539172.1
T8930.515127.90.4

MCP-1 -2518

Genotypes
AA8654.417058.20.4
AG6138.610034.20.3
GG117227.50.8
Alleles
A23373.744075.3
G8326.314424.70.6
Relationship between RANTES, IL-8, MCP-1 and IL-1α polymorphisms and the presence of nephritis in SLE Spanish patients. Similarly, no significant differences were observed between all these genetic variants and the following variables: sex, age at onset, articular involvement, cutaneous lesions, photosensitivity, hematological alterations, neurological disorders and serositis (data not shown).

Discussion

In this work, we have tested six functional polymorphisms of four strong candidate genes for association with SLE. No evidence of association was detected for RANTES (-403 G/A, R3 T/C),IL-8 (-353 A/T, +781 C/T), IL-1α (-889C/T), and MCP-1 (-2518 G/A) polymorphisms. However, a significant association was observed for the IL-8 haplotype with SLE nephritis, which cannot be considered as significant after correction for multiple comparisons. All these genes have been previously associated with susceptibility and development to several autoimmune disorders, included SLE [16,21-27]. For example, recent studies in Asian populations found another RANTES polymorphism (-28C/G) to be associated with increased risk of developing SLE, but failed to detect any association of RANTES -403 polymorphisms with SLE [22,23]. We did not test the -28C/G variant as -28G allele is relatively uncommon in Caucasians [28]. The genetic variant IL-8 -845C showed a high association to severe lupus nephritis (LN) in an African American population [16], but also this allele has a very low frequency in Caucasian populations [16,29]. The trend of association that we have found between the haplotypes and LN and the reported association of other IL-8 variants this African American population, shows that variants in this chemokine may have a minor influence on the risk of developing nephritis in SLE patients. Similar observation could be made for the reported association of the IL-1α -889C/T variant to SLE in a White and African American populations from United States, which we failed to replicate [30]. With regard to the MCP-1 -2518 polymorphism, an American study showed that an A/G or G/G genotype may predispose to the development of SLE and further indicated that SLE patients with these genotypes may be at higher risk of developing LN [3]. The fact that we do not observe an association and fail to confirm some previous studies may be caused by a Type II error (false-negative). This is however unlikely because our sample has more than 80% power to detect the relative risk similar to the other studies at the 5% significance level. Furthermore, the genotype frequencies did not differ from Hardy-Weinberg expectations, and allele and genotype frequencies in our Spanish population are similar to those reported previously in other Caucasian populations [16,26,31,32]. The failure to replicate reported associations is a common event in the search for genetic determinants of complex diseases, due either to genuine population heterogeneity or a different sort of bias [33]. The lack of replication in our population may alternatively be explained by a different racial composition of that study from ours, or that presence of environmental factors to which the Asian, American, and African populations, but not the Spanish population, are exposed. In addition, genetic differences are known to exist between the different ethnic groups, such as, African American and Caucasians.

Conclusion

In conclusion, our results suggest that functional genetics variation in RANTES, IL-8, IL-1α, and MCP-1 do not play a major role in SLE susceptibility in the Spanish population.

Competing interests

The author(s) declare that they have no competing interests.

Authors' contributions

ES carried out the genotyping and statistical analysis and drafted the manuscript, JMS collected the samples, JLC collected the samples, EDR collected the samples, RGP collected the samples, FJGH collected the samples, JJA collected the samples, MFGE collected the samples, JM participated in the manuscript design and coordination and helped to draft the manuscript, BK participated in the manuscript design, reviewed the statistical analysis and helped to draft the manuscript.

Pre-publication history

The pre-publication history for this paper can be accessed here:
  33 in total

1.  Novel single nucleotide polymorphisms in the distal IL-10 promoter affect IL-10 production and enhance the risk of systemic lupus erythematosus.

Authors:  A W Gibson; J C Edberg; J Wu; R G Westendorp; T W Huizinga; R P Kimberly
Journal:  J Immunol       Date:  2001-03-15       Impact factor: 5.422

2.  Replication validity of genetic association studies.

Authors:  J P Ioannidis; E E Ntzani; T A Trikalinos; D G Contopoulos-Ioannidis
Journal:  Nat Genet       Date:  2001-11       Impact factor: 38.330

3.  The polymorphism of monocyte chemoattractant protein-1 is associated with the renal disease of SLE.

Authors:  Hyun Lee Kim; Dong-Sup Lee; Seung Hee Yang; Chun Soo Lim; Jong Hoon Chung; Suhnggwon Kim; Jung Sang Lee; Yo Su Kim
Journal:  Am J Kidney Dis       Date:  2002-12       Impact factor: 8.860

4.  MCP-1 promoter polymorphism in Spanish patients with systemic lupus erythematosus.

Authors:  F Aguilar; M F González-Escribano; J Sánchez-Román; A Núñez-Roldán
Journal:  Tissue Antigens       Date:  2001-11

5.  Cloning and functional analysis of the allelic polymorphism in the transcription regulatory region of interleukin-1 alpha.

Authors:  Roberto Dominici; Monica Cattaneo; Giulia Malferrari; Davide Archi; Claudio Mariani; Luigi Maria Edoardo Grimaldi; Ida Biunno
Journal:  Immunogenetics       Date:  2002-03-19       Impact factor: 2.846

6.  RANTES promoter polymorphism as a genetic risk factor for rheumatoid arthritis in the Chinese.

Authors:  C-R Wang; H-R Guo; M-F Liu
Journal:  Clin Exp Rheumatol       Date:  2005 May-Jun       Impact factor: 4.473

7.  Chemokine RANTES promoter polymorphism affects risk of both HIV infection and disease progression in the Multicenter AIDS Cohort Study.

Authors:  D H McDermott; M J Beecroft; C A Kleeberger; F M Al-Sharif; W E Ollier; P A Zimmerman; B A Boatin; S F Leitman; R Detels; A H Hajeer; P M Murphy
Journal:  AIDS       Date:  2000-12-01       Impact factor: 4.177

8.  Polymorphisms in the promoter region of RANTES in Han Chinese and their relationship with systemic lupus erythematosus.

Authors:  Dong Qing Ye; Shi Gui Yang; Xiang Pei Li; Yi Song Hu; Jing Yin; Guo Qing Zhang; Hui Hui Liu; Qian Wang; Ke Chun Zhang; Ma Xia Dong; Xue Jun Zhang
Journal:  Arch Dermatol Res       Date:  2005-09-29       Impact factor: 3.017

9.  A novel interleukin-8 polymorphism is associated with severe systemic lupus erythematosus nephritis.

Authors:  Brad H Rovin; Ling Lu; Xiaolan Zhang
Journal:  Kidney Int       Date:  2002-07       Impact factor: 10.612

10.  IL-1 genes in myasthenia gravis: IL-1A -889 polymorphism associated with sex and age of disease onset.

Authors:  Francesca L Sciacca; Cinzia Ferri; Fabrizio Veglia; Francesca Andreetta; Renato Mantegazza; Ferdinando Cornelio; Diego Franciotta; Giovanni Piccolo; Vittorio Cosi; Anna P Batocchi; Amelia Evoli; Luigi M E Grimaldi
Journal:  J Neuroimmunol       Date:  2002-01       Impact factor: 3.478

View more
  19 in total

1.  Association of MCP-1-2518A/G polymorphism with susceptibility to autoimmune diseases: a meta-analysis.

Authors:  Si Chen; Chuiwen Deng; Chaojun Hu; Jing Li; Xiaoting Wen; Ziyan Wu; Yuan Li; Fengchun Zhang; Yongzhe Li
Journal:  Clin Rheumatol       Date:  2015-08-29       Impact factor: 2.980

2.  Lack of association of vitamin D receptor gene BsmI polymorphisms in patients with systemic lupus erythematosus.

Authors:  Mahnaz Abbasi; Zahra Rezaieyazdi; Jalil Tavakol Afshari; Mohammadreza Hatef; Maryam Sahebari; Nayereh Saadati
Journal:  Rheumatol Int       Date:  2010-05-15       Impact factor: 2.631

3.  A population association study of vitamin D receptor gene polymorphisms and haplotypes with the risk of systemic lupus erythematosus in a Chinese population.

Authors:  Xu-E Chen; Pu Chen; Shan-Shan Chen; Jin Lu; Ting Ma; Guang Shi; Ya Zhou; Ji Li; Liang Sheng
Journal:  Immunol Res       Date:  2017-06       Impact factor: 2.829

4.  Meta-analysis of MCP-1 promoter -2518 A/G polymorphism and SLE susceptibility.

Authors:  Ting Liu; Jin-Xia Zhai; Han-Yong Wang; Xing-Hua Wang; Li-Wei Zou; Wen-Jing Fan; Dong-Qing Ye
Journal:  Mol Biol Rep       Date:  2012-06-17       Impact factor: 2.316

5.  Genetic variability of interleukin-1 beta as prospective factor from developing post-traumatic stress disorder.

Authors:  Lilit Hovhannisyan; Ani Stepanyan; Arsen Arakelyan
Journal:  Immunogenetics       Date:  2017-07-05       Impact factor: 2.846

6.  Interleukin 8 and susceptibility to coronary artery disease: a population genetics perspective.

Authors:  Konstantina Vogiatzi; Stavros Apostolakis; Vassilios Voudris; Sophia Thomopoulou; Georgios E Kochiadakis; Demetrios A Spandidos
Journal:  J Clin Immunol       Date:  2008-04-02       Impact factor: 8.317

7.  Association of RANTES and MBL gene polymorphisms with systemic lupus erythematosus: a meta-analysis.

Authors:  Wang-Dong Xu; Hui Peng; Mo Zhou; Min Zhang; Bao-Zhu Li; Hai-Feng Pan; Dong-Qing Ye
Journal:  Mol Biol Rep       Date:  2012-10-13       Impact factor: 2.316

8.  Monocyte chemoattractant protein-1 -2518 A/G single nucleotide polymorphism might be associated with renal disease and thrombocytopenia of SLE.

Authors:  Piotr Piotrowski; Margarita Lianeri; Robert Gasik; Andrzej Roszak; Marzena Olesińska; Paweł P Jagodziński
Journal:  J Biomed Biotechnol       Date:  2010-04-21

9.  Functional monocyte chemoattractant protein-1 promoter -2518 polymorphism and systemic lupus erythematosus: a meta-analysis.

Authors:  Young Ho Lee; Jin-Hyun Woo; Sung Jae Choi; Jong Dae Ji; Gwan Gyu Song
Journal:  Mol Biol Rep       Date:  2009-11-26       Impact factor: 2.316

10.  Interleukin-8 promoter polymorphism -251A/T is a risk factor for age-related macular degeneration.

Authors:  S V Goverdhan; S Ennis; S R Hannan; K C Madhusudhana; A J Cree; A J Luff; A J Lotery
Journal:  Br J Ophthalmol       Date:  2008-02-29       Impact factor: 4.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.